| |
Etoposide and teniposide, the epipodophyllotoxins, stabilize the double stranded DNA cleavage
normally catalyzed by topoisomerase II and inhibit faithful religation of DNA breaks (PMID: 1681541; 9748545).
These double-strand DNA breaks subsequently trigger the desired antitumor effects of the drugs. Metabolism of
etoposide is mediated by CYP3A4 and CPY3A5 (PMID: 8114683; 15319341), both of which are transcriptionally
regulated by NR1I2 (i.e. Pregnane X receptor). Thus, xenobiotics that modulate NR1I2 activity (e.g.
dexamethasone and rifampicin) have been observed to enhance etoposide clearance (PMID: 15578943; 12969965).
In addition to CYP3A4/5 mediated reactions, conversion of etoposide to the O-demethylated metabolites (catechol
and quinone) can also be catalyzed by prostaglandin synthases or myeloperoxidase (PMID: 3006680; 16841962; 11691792).
These metabolites have similar potency at inhibiting topoisomerase II and are more oxidatively reactive than
the parent drug (PMID: 11170441). Glutathione and glucuronide conjugation appear to inactivate parent drug
and metabolite, and are mediated by GSTT1/GSTP1 and UGT1A1, respectively (PMID: 1315544; 3167829; 17151191;
12695346). Efflux of conjugated or unconjugated forms of etoposide has been associated with ABCC1, ABCC3
and ABCB1 (PMID: 8640791; 11581266), representing plausible mechanisms of drug resistance. Epipodophyllotoxins
are highly effective anticancer agents, but can cause a delayed toxicity: treatment-related acute myeloid
leukemia or myelodysplastic syndrome (t-ML) (PMID: 18509329; 1944468; 2822173). Drug-induced formation of
MLL fusion genes has been associated with the development of t-ML (PMID: 8260707). Even though etoposide
inhibits both topo II alpha and beta, the anti-tumor activity of etoposide is shown to be delivered
primarily through inhibition of topo II alpha (PMID: 11531262) whilst the carcinogenic effect has
been attributed to the beta isoform (PMID: 17578914). Recently, 64 genetic variants that contribute
to etoposide-induced cytotoxicity were identified through a whole-genome association study (PMID: 17537913).
|
Jun Yang,1 Alessia Bogni,1 Erin G. Schuetz,1
Mark Ratain,2 M. Eileen Dolan,2 Howard McLeod,3 Caroline Thorn,4 Li Gong,4
and Mary V. Relling 1
1. Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN;
2. Department of Medicine, University of Chicago;
3. Department of Medicine, Washington University School of Medicine, St. Louis, MO;
4. PharmGKB, Stanford University, Palo Alto, CA. |
| Simon Joel |
|
Pharmacogenet Genomics. 2009 Jul;19(7):552-553. PMID: 19512958
|
| May 27, 2004 |
| July 22, 2009 |
|